Immatics: PRAME Is Evolving Into a Multi-Modal Franchise — Time to Own the Story
Recent ASCO data and multiple positive signals across Immatics' PRAME programs (anzu-cel/IMA203 and next-gen assets) argue that PRAME is becoming a platform rather than a single therapy. With a market cap of $1.27B, a $125M equity raise behind it, and a Phase 3 program on track for BLA submission in H1 2027, Immatics presents a high-reward long tra…